{"analyses":[{"ciLowerLimit":"1.25","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.89","groupDescription":"Hazard Ratio, and Confidence Interval were based on analyses on all randomized subjects","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.54","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.8","upperLimit":"11.8","value":"9.3"},{"groupId":"OG001","lowerLimit":"12.2","upperLimit":"18.2","value":"15.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"167"}],"units":"Participants"}],"description":"The time to MMR for all randomized participants is defined as the time from randomization date until measurement criteria are first met for MMR. The time to MMR analysis censors nonresponders who do not progress at their last molecular assessments and nonresponders who progress at the maximum time of all randomized participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tablets, oral, dasatinib 100 mg once daily (QD)","id":"OG000","title":"Dasatinib"},{"description":"Tablets, oral, imatinib 400 mg once daily (QD)","id":"OG001","title":"Imatinib"}],"paramType":"MEDIAN","populationDescription":"All participants who received treatment and achieved MMR","reportingStatus":"POSTED","timeFrame":"Day 1 to 5 years","title":"Time to Major Molecular Response (MMR) Overall","type":"SECONDARY","unitOfMeasure":"Months"}